DOCSLIB.ORG

Neuroprotective Effect of MK-801 Against Intra-Striatal Quinolinic Acid Induced Behavioral, Oxidative Stress and Cellular Alterations in Rats

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuroprotective Effect of MK-801 Against Intra-Striatal Quinolinic Acid Induced Behavioral, Oxidative Stress and Cellular Alterations in Rats Indian Journal of Experimental Biology Vol. 47, November 2009, pp. 880-892 Neuroprotective effect of MK-801 against intra-striatal quinolinic acid induced behavioral, oxidative stress and cellular alterations in rats Harikesh Kalonia1, Puneet Kumar1, Bimla Nehru2 & Anil Kumar1,* 1Pharmacology Division, University Institute of Pharmaceutical Sciences, UGC Centre for Advanced Studies, Panjab University, Chandigarh 160 014, India 2 Department of Biophysics, Panjab University, Chandigarh 160014, India Received 22 February 2009; revised 22 June 2009 Huntington’s Disease (HD) is a common neurodegenerative disorder characterized by motor disturbances, subcortical dementia and psychiatric disturbances. Pathogenesis of HD revolves so far around excitatory amino acids as the primary cause of neuronal loss. However, number of recent reports suggests the involvement of excitotoxicity and oxidative damage. In the present study, first the dose of quinolinic acid that mimics the symptoms of HD was standardized and then the neuroprotective effect of MK-801 (noncompetitive NMDAr antagonist) was evaluated against intrastriatal quinolinic acid induced behavioral, oxidative stress and cellular alterations in rats. A single unilateral (ipsilateral striatum) injections of quinolinic acid (100, 200 and 300 nM) were made in to striatum. Animals were tested for motor functions using actophotometer and rotarod apparatus. Quinolinic acid (300 nM) significantly reduced the body weight and caused motor in-coordination and produced oxidative damage in the cortex and striatum as indicated by raised lipid peroxidation, nitrite concentration, depletion of superoxide dismutase, catalase and different glutathione levels. Beside, quinolinic acid (300 nM) significantly altered the mitochondrial enzymes complex levels and caused histopathological alterations in the striatum. MK-801(0.02, 0.04, 0.08 mg/kg, ip) treatment significantly improved body weight, behavioral alterations (locomotor activity and rotarod performance) and attenuated oxidative damage and mitochondrial enzymes complex dysfunction. Besides, MK-801 treatment significantly reversed histopathological alterations in striatum. The results suggest antioxidant and neuroprotective action of MK-801 against the quinolinic acid induced Huntington’s like behavioral, oxidative stress and cellular alterations in rats. Keywords: Glutathione, Huntington’s disease, Mitochondrial dysfunction, MK-801, Oxidative Stress, Quinolinic acid, Striatum Huntington’s disease (HD) is a common this metabolite (5-10-fold in early stage HD patients), neurodegenerative disorder characterized by together with 3-hydroxykynurenine (3-HK), dementia, choreiform movements1 and degeneration (kynurenine metabolite) increased reactive oxygen of basal ganglia (caudate putamen) including cortex. species (ROS) formation in the striatum and cortex of Beside, irritability, obsessions, compulsions, HD brains. These findings explain the role of the hallucinations, altered family dynamics and decreased QUIN in HD pathogenesis and similarity with clinical executive functions in HD patients2,3. Presently, there symptoms7. QUIN is an endogenous tryptophan is no suitable drug treatment available for the metabolite that causes excitotoxicity by acting on N- effective management of this disease. Pathogenesis of methyl-D-aspartate receptor (NMDAr) subtype8,9. As HD has not been fully understood so far. However, a heterocyclic amino acid derived from L-tryptophan, key mechanism of neuronal death revolves around QUIN is a precursor of NAD+ at the kynurenine excitotoxicity, impaired energy metabolism, pathway5. QUIN causes excitotoxicity by stimulating neuroinflammation and oxidative damage4. NMDAr, causing membrane depolarization and Quinolinic acid (QUIN) (2, 3-pyridine calcium influx in the neurons, which in turn, results in decarboxylic acid) has been reported to produce HD activation of proteases, lipases, generation of free like symptoms as observed in HD patients5,6. Recent radicals, constitutive nitric oxide synthase (NOS), findings reinforced the consideration that the levels of disruption of mitochondrial oxidative phosphorylation and enhanced brain lipid peroxidation8,10-13. In ________________ addition, alterations in the number of NMDAr have *Correspondent author also been suggested to be other components of the Telephone: +91-172-2534106 Fax: +91-172-2541142 glutamatergic transmission, involved as causative 3 E-mail: [email protected] factors in HD pathogenesis . KALONIA et al.: MK-801 AGAINST QUINOLINIC ACID INDUCED ALTERATIONS IN RATS 881 MK-801 [(+)-5-methyl-10, 11-dihydro-5H- Intrastriatal administration of QUIN — Animals dibenzo-cyclo-hepten-5, 10-imine maleate] is a potent were anesthetized with thiopental sodium (45mg/kg, ip). selective and noncompetitive NMDA receptor The surface of the skull was exposed by making incision antagonist14. Upon systemic administration, MK-801 on the scalp. QUIN injections were made into the right prevents damage of striatal and hippocampal neurons striatum by means of a 28-gauge stainless steel needle caused by direct injection of NMDA15. MK-801, non- attached to a Hamilton syringe. Injections were made via competitive NMDA receptor antagonist has been a l-2 mm diameter hole made in the skull using a small reported to enhance locomotor activity in rodents15. hand drill at anterior +1.7mm; lateral±2.7mm; ventral- Non competitive NMDA antagonist affects 4.8mm from bregma and dura as described in Paxinos locomotion by increasing dopamine (DA) turnover in and Watson20. QUIN was injected in a volume of 4 µl mesolimbic structures and through NMDA receptor delivered over a period of 2 min, and injection needle antagonism. MK-801 inhibits the uptake of dopamine. was left in place for another 1.5 min to allow diffusion MK-801 is a highly selective for NMDA recognition of the injected drug solution. site and shows low affinity for the DA uptake site. Therefore, MK-801-induced hyperlocomotion is Behavioral assessments mediated, at least in part, by NMDA receptor Body weight change — The body weight of antagonism. Studies reported the protective action of animals was recorded before the start of drug the MK-801 in the various neurodegenerative treatment (before QUIN administration) and on last psychological disorders such as depression, epilepsy, day of the study thereafter behavioral quantification. ischemia, alzheimers etc16-19. Aim of the present study Assessment of gross behavioral activity was to evaluate the antioxidant and neuroprotective (Locomotor activity) — The locomotor activity was action of MK-801 (NMDAr antagonist) against the assessed by using actophotometer (IMCORP, India) st th th st QUIN induced HD like behavioral, oxidative stress on day 1 , 7 , 14 and 21 . Animals were placed and cellular alterations in the rats. individually in the activity chamber for 3 min as a habituation period before making actual motor Materials and Methods activity tasks monitoring for next 5 min. Total activity Animals — Male Wistar rats (132) bred in Central (horizontal and vertical) were expressed as counts per Animal House, Panjab University, Chandigarh and 5 min as described by Kulkarni21. The apparatus was weighing between 220-250 g were used. The animals placed in a darkened, light and sound attenuated and were kept under standard laboratory conditions, ventilated testing room during the assessment. maintained on 12-h light/dark cycle and had free access Rotarod activity — All animals were evaluated for to food and water. Animals were acclimatized to motor coordination and balance on rotarod test on 1st, 7th, laboratory conditions before the test. All the experiments 14th and 21st day after QUIN injection. The animals were were performed between 9.00 and 17.00 hrs. The given a prior training session before actual recording on experimental protocol was approved by Institutional rotarod apparatus (IMCORP, Ambala, India) to Animal Ethics Committee and conducted according to acclimatize. Rats were placed on the rotating rod with a the Indian National Science Academy Guidelines for the diameter of 7 cm (speed 25 rpm). The cut off time use and care of experimental animals. (90 sec) was fixed and each rat performed three separate Drug and treatment schedule — QUIN (Sigma trials at 5 min interval as described by Kulkarni21. Chemical, India) was dissolved in normal saline and administered unilaterally in the striatum (4 µl). Biochemical assessments Animals were divided into following 11 groups, of Dissection and homogenization — On 21st day, 12 animals each: Group-1 naïve (without surgery); animals were sacrificed by decapitation immediately group-2 sham (surgery without intra striatal injection) after behavioral assessments. The brains were received normal saline; Group 3-5 received dissected and cerebellum discarded. Cortex and intrastriatal QUIN 100, 200 and 300 nM single striatum were separated by putting on ice and then injection respectively; Group 6-8 received MK-801 weighted separately. A 10% (w/v) tissue homogenate (0.02, 0.04 and 0.08 mg/kg, ip). However, MK-801 was prepared in 0.1 M phosphate buffer (pH 7.4). The (0.02, 0.04 and 0.08 mg/kg, ip) treatment against homogenate was centrifuged at 10,000 g for 15 min intrastriatal QUIN 300 nM administration was and aliquots of supernatant was separated and used considered as group 9-11 respectively. for biochemical estimations. 882 INDIAN J EXP BIOL, NOVEMBER 2009 Lipid peroxidation assay — The quantitative Complex-I (NADH dehydrogenase activity) — was measurement
Load more

Recommended publications
  • The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
    The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons Abdur Rahman1,4., Kaka Ting2, Karen M. Cullen3, Nady Braidy4, Bruce J. Brew2,5, Gilles J. Guillemin2,4.* 1 Department of Family Sciences, College for Women, Kuwait University, Shuwaikh, Kuwait, 2 St Vincent’s Hospital, Centre for Applied Medical Research, Department of Neuroimmunology, Darlinghurst, New South Wales, Australia, 3 Disciplines of Anatomy and Histology, School of Medical Science, The University of Sydney, New South Wales, Australia, 4 Department of Pharmacology, University of New South Wales, School of Medical Science, Sydney, New South Wales, Australia, 5 Department of Neurology, St Vincent’s Hospital, Darlinghurst, New South Wales, Australia Abstract Some of the tryptophan catabolites produced through the kynurenine pathway (KP), and more particularly the excitotoxin quinolinic acid (QA), are likely to play a role in the pathogenesis of Alzheimer’s disease (AD). We have previously shown that the KP is over activated in AD brain and that QA accumulates in amyloid plaques and within dystrophic neurons. We hypothesized that QA in pathophysiological concentrations affects tau phosphorylation. Using immunohistochemistry, we found that QA is co-localized with hyperphosphorylated tau (HPT) within cortical neurons in AD brain. We then investigated in vitro the effects of QA at various pathophysiological concentrations on tau phosphorylation in primary cultures of human neurons. Using western blot, we found that QA treatment increased the phosphorylation of tau at serine 199/202, threonine 231 and serine 396/404 in a dose dependent manner. Increased accumulation of phosphorylated tau was also confirmed by immunocytochemistry. This increase in tau phosphorylation was paralleled by a substantial decrease in the total protein phosphatase activity.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information Quinolinic Acid Item No. 14941 CAS Registry No.: 89-00-9 Formal Name: 2,3-pyridinedicarboxylic acid Synonyms: NSC 13127, NSC 18836, NSC 403247 O N MF: C7H5NO4 FW: HO 167.1 HO Purity: ≥98% Stability: ≥2 years at -20°C Supplied as: A crystalline solid O λ UV/Vis.: max: 216, 264 nm Laboratory Procedures For long term storage, we suggest that quinolinic acid be stored as supplied at -20°. It should be stable for at least two years. Quinolinic acid is supplied as a crystalline solid. A stock solution may be made by dissolving the quinolinic acid in the solvent of choice. Quinolinic acid is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of quinolinic acid in these solvents is approximately 16 mg/ml. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of quinolinic acid can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of quinolinic acid in PBS, pH 7.2, is approximately 0.5 mg/ml. We do not recommend storing the aqueous solution for more than one day. Quinolinic acid is an endogenous agonist at NMDA receptors that is generated through the metabolism of tryptophan in the kynurenine pathway.1 By overactivating NMDA receptors, quinolinic acid produces neurotoxicity, which has been implicated in certain neurodegenerative disorders.2 Quinolinic acid can also generate reactive oxygen species, has immunomodulatory actions, and promotes the formation of hyperphosphorylated tau proteins.3-5 References 1.
    [Show full text]
  • Linking Phencyclidine Intoxication to the Tryptophan-Kynurenine Pathway Therapeutic Implications for Schizophrenia
    Neurochemistry International 125 (2019) 1–6 Contents lists available at ScienceDirect Neurochemistry International journal homepage: www.elsevier.com/locate/neuint Linking phencyclidine intoxication to the tryptophan-kynurenine pathway: Therapeutic implications for schizophrenia T ∗ Hidetsugu Fujigakia, ,1, Akihiro Mourib,c,1, Yasuko Yamamotoa, Toshitaka Nabeshimac,d, Kuniaki Saitoa,c,d,e a Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470- 1192, Japan b Department of Regulatory Science, Fujita Health University Graduate School of Health Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan c Japanese Drug Organization of Appropriate Use and Research, 3-1509 Omoteyama, Tenpaku-ku, Nagoya, Aichi 468-0069, Japan d Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan e Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan ARTICLE INFO ABSTRACT Keywords: Phencyclidine (PCP) is a dissociative anesthetic that induces psychotic symptoms and neurocognitive deficits in Phencyclidine rodents similar to those observed in schizophrenia patients. PCP administration in healthy human subjects in- Kynurenic acid duces schizophrenia-like symptoms such as positive and negative symptoms, and a range of cognitive deficits. It Quinolinic acid has been reported that PCP, ketamine, and related drugs such as N-methyl-D-aspartate-type (NMDA) glutamate Kynurenine pathway receptor antagonists, induce behavioral effects by blocking neurotransmission at NMDA receptors. Further, Schizophrenia NMDA receptor antagonists reproduce specific aspects of the symptoms of schizophrenia.
    [Show full text]
  • Systemic Approaches to Modifying Quinolinic Acid Striatal Lesions in Rats
    The Journal of Neuroscience, October 1988, B(10): 3901-3908 Systemic Approaches to Modifying Quinolinic Acid Striatal Lesions in Rats M. Flint Beal, Neil W. Kowall, Kenton J. Swartz, Robert J. Ferrante, and Joseph B. Martin Neurology Service, Massachusetts General Hospital, and Department of Neurology, Harvard Medical School, Boston, Massachusetts 02114 Quinolinic acid (QA) is an endogenous excitotoxin present mammalian brain, is an excitotoxin which producesaxon-spar- in mammalian brain that reproduces many of the histologic ing striatal lesions. We found that this compound produced a and neurochemical features of Huntington’s disease (HD). more exact model of HD than kainic acid, sincethe lesionswere In the present study we have examined the ability of a variety accompaniedby a relative sparingof somatostatin-neuropeptide of systemically administered compounds to modify striatal Y neurons (Beal et al., 1986a). QA neurotoxicity. Lesions were assessed by measurements If an excitotoxin is involved in the pathogenesisof HD, then of the intrinsic striatal neurotransmitters substance P, so- agentsthat modify excitotoxin lesionsin vivo could potentially matostatin, neuropeptide Y, and GABA. Histologic exami- be efficacious as therapeutic agents in HD. The best form of nation was performed with Nissl stains. The antioxidants therapy from a practical standpoint would be a drug that could ascorbic acid, beta-carotene, and alpha-tocopherol admin- be administered systemically, preferably by an oral route. In the istered S.C. for 3 d prior to striatal QA lesions had no sig- presentstudy we have therefore examined the ability of a variety nificant effect. Other drugs were administered i.p. l/2 hr prior of systemically administered drugs to modify QA striatal neu- to QA striatal lesions.
    [Show full text]
  • NMDA Agonists Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of NMDA Agonists Using ALZET Osmotic Pumps Aspartic Acid P7453: M. Domercq, et al. Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. Glia 2005;52(1):36-46 ALZET Comments: Oligonucleotide, antisense; oligonucleotide sense; kainate, dihydro-; aspartic acid, DL-threo-B-benzyloxy-; Saline, sterile; CSF/CNS (optic nerve); Rabbit; 1003D; 3 days; Controls received mp w/ vehicle, or contralateral nerves; antisense (glutamate transporters GLAST + GLT-1); animal info (adult, male, white New Zealand). P6888: J. Darman, et al. Viral-induced spinal motor neuron death is non-cell-autonomous and involves glutamate excitotoxicity. Journal of Neuroscience 2004;24(34):7566-7575 ALZET Comments: Aspartic acid, dl-threo-B-hydroxy; spermine, 1-naphthyl acetyl; CSF/CNS (intrathecal, subarachnoid space); Rat; 1007D; 7 days; Controls received mp w/ saline; enzyme inhibitors (GLT-1, GluR2). P3908: A. Hirata, et al. AMPA receptor-mediated slow neuronal death in the rat spinal cord induced by long-term blockade of glutamate transporters with THA. Brain Research 1997;771(37-44 ALZET Comments: Aspartic acid, dl-threo-B-hydroxy; Glutamate, l-; CSF, artificial;; CSF/CNS (subarachnoid space, intrathecal); Rat; 2ML1; no duration posted; dose-response; cannula position verified. P0289: R. M. Mangano, et al. Chronic infusion of endogenous excitatory amino acids into rat striatum and hippocampus. Brain Res. Bull 1983;10(47-51 ALZET Comments: Aminobutyric acid, Y-; Aspartic acid, dl-threo-B-hydroxy; Aspartic acid, l-; Cysteine sulfinic acid; Glutamic acid, l-; Radio-isotopes; 3H tracer; Acetate; Saline; CSF/CNS (corpus striatum); CSF/CNS (hippocampus); Rat; 2002; 2 weeks; comparison of injec.
    [Show full text]
  • Inflammation, Insulin Resistance and the Pathophysiology of Depression: Implications for Novel Antidepressant Developments
    REVIEW ARTICLE Psychiatry and Clinical Psychopharmacology 2020;30(1):71-80 DOI: 10.5455/PCP.20200215032026 Inflammation, Insulin Resistance and the Pathophysiology of Depression: Implications for Novel Antidepressant Developments Brian E. Leonarda, Feyza Aricioglub a Department of Pharmacology and Therapeutics,National University of Ireland, Galway, b Department of Pharmacology and Psychopharmacology Research Unit University of Marmara, Istanbul, Turkey Abstract This review summarises the impact of chronic low grade inflammation as a causative factor in the pathophysiology of major depression. Evidence is presented to show that proinflammatory cytokines both directly, and indirectly by increasing hypercortisolaemia, desensitise insulin receptors and thereby ARTICLE HISTORY decrease the transport of glucose into the brain (the diabetic brain). In addition, the proinflammatory Received: May 30, 2019 cytokines activate the tryptophan-kynurenine pathway which results in the synthesis of the NMDA- Accepted: Jan 29, 2020 glutamate receptor agonist quinolinic acid. This acts as a neurotoxin and facilitates neuronal apoptosis. As metabolic changes initiated by low grade inflammation underlie the pathophysiology of depression, drugs which attenuate the inflammatory cascade may present an approach to the KEYWORDS: inflammation, novel development of antidepressants. The review concludes with a summary of drugs which might insulin resistance, depression be considered for their novel therapeutic activity. Key points are; i)Chronic low grade inflammation
    [Show full text]
  • The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
    The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons Abdur Rahman1,4., Kaka Ting2, Karen M. Cullen3, Nady Braidy4, Bruce J. Brew2,5, Gilles J. Guillemin2,4.* 1 Department of Family Sciences, College for Women, Kuwait University, Shuwaikh, Kuwait, 2 St Vincent’s Hospital, Centre for Applied Medical Research, Department of Neuroimmunology, Darlinghurst, New South Wales, Australia, 3 Disciplines of Anatomy and Histology, School of Medical Science, The University of Sydney, New South Wales, Australia, 4 Department of Pharmacology, University of New South Wales, School of Medical Science, Sydney, New South Wales, Australia, 5 Department of Neurology, St Vincent’s Hospital, Darlinghurst, New South Wales, Australia Abstract Some of the tryptophan catabolites produced through the kynurenine pathway (KP), and more particularly the excitotoxin quinolinic acid (QA), are likely to play a role in the pathogenesis of Alzheimer’s disease (AD). We have previously shown that the KP is over activated in AD brain and that QA accumulates in amyloid plaques and within dystrophic neurons. We hypothesized that QA in pathophysiological concentrations affects tau phosphorylation. Using immunohistochemistry, we found that QA is co-localized with hyperphosphorylated tau (HPT) within cortical neurons in AD brain. We then investigated in vitro the effects of QA at various pathophysiological concentrations on tau phosphorylation in primary cultures of human neurons. Using western blot, we found that QA treatment increased the phosphorylation of tau at serine 199/202, threonine 231 and serine 396/404 in a dose dependent manner. Increased accumulation of phosphorylated tau was also confirmed by immunocytochemistry. This increase in tau phosphorylation was paralleled by a substantial decrease in the total protein phosphatase activity.
    [Show full text]
  • Quinolinic Acid Toxicity on Oligodendroglial Cells
    Sundaram et al. Journal of Neuroinflammation (2014) 11:204 JOURNAL OF DOI 10.1186/s12974-014-0204-5 NEUROINFLAMMATION RESEARCH Open Access Quinolinic acid toxicity on oligodendroglial cells: relevance for multiple sclerosis and therapeutic strategies Gayathri Sundaram1,2, Bruce J Brew1,3, Simon P Jones1, Seray Adams2,4, Chai K Lim1,2,4 and Gilles J Guillemin1,2,4* Abstract The excitotoxin quinolinic acid, a by-product of the kynurenine pathway, is known to be involved in several neurological diseases including multiple sclerosis (MS). Quinolinic acid levels are elevated in experimental autoimmune encephalomyelitis rodents, the widely used animal model of MS. Our group has also found pathophysiological concentrations of quinolinic acid in MS patients. This led us to investigate the effect of quinolinic acid on oligodendrocytes; the main cell type targeted by the autoimmune response in MS. We have examined the kynurenine pathway (KP) profile of two oligodendrocyte cell lines and show that these cells have a limited threshold to catabolize exogenous quinolinic acid. We further propose and demonstrate two strategies to limit quinolinic acid gliotoxicity: 1) by neutralizing quinolinic acid’s effects with anti-quinolinic acid monoclonal antibodies and 2) directly inhibiting quinolinic acid production from activated monocytic cells using specific KP enzyme inhibitors. The outcome of this study provides a new insight into therapeutic strategies for limiting quinolinic acid-induced neurodegeneration, especially in neurological disorders that target oligodendrocytes, such as MS. Keywords: Multiple sclerosis, Oligodendrocyte, Quinolinic acid, Excitotoxicity, Neurodegeneration, Neuroinflammation Introduction balance between excessive production of neurotoxic me- Quinolinic acid (QUIN) is a downstream metabolite pro- tabolites, such as QUIN, and neuroprotective compounds, duced through the kynurenine pathway (KP) of trypto- such as kynurenic acid (KYNA) [6,7].
    [Show full text]
  • (NMDA) Receptors and L-Arginine-Nitric Oxide Pathway
    JKAU: Med. Sci., Vol. 20 No. 1, pp: 81-95 (2013 A.D. / 1434 A.H.) DOI: 10.4197/Med. 20-1.6 Agmatine’s Antidepressant-like Effect in Mice: Possible Contribution of N-Methyl-D-Aspartate (NMDA) Receptors and L-Arginine-Nitric Oxide Pathway Abdulrahman M. Alahdal, PharmD, Atef A. Al-Essawy, MD PhD and Amen M. Almohammadi, PharmD PhD Department of Clinical Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia [email protected] Abstract. In a mammalian brain, agmatine is an endogenous neurotransmitter and/or neuromodulator which is considered an endogenous ligand for α2-adrenergic and imidazoline receptors. It blocks N-methyl-D- aspartate subtype of glutamate receptors and inhibits all isoforms of nitric oxide synthases. Both, N-methyl-D-aspartate receptors and nitric oxide system have been implicated in the regulation of various behavioral, cognitive and emotional processes e.g. learning, aggression, locomotion, anxiety and depression. This study aimed at investigating the antidepressant- like effect of agmatine and the possible participation of N-methyl-D- aspartate receptors and L-arginine-nitric oxide pathway in this effect. Agmatine (1, 10, 50 mg/kg, i.p.) possessed an antidepressant-like effect in two experimental models of depression; the forced swimming test and the tail suspension test in mice. Agmatine significantly enhanced the anti- immobility effect of imipramine, but did not affect that of ketamine (noncompetitive N-methyl-D-aspartate antagonist). The anti-immobility effect of agmatine assessed in the forced swimming test was completely prevented by pretreatment of mice with ascorbic acid (neuromodulator that antagonizes N-methyl-D-aspartate) or L-arginine (nitric oxide precursor).
    [Show full text]
  • L-Tryptophan, the FDA, and the Regulation of Amino Acids Carter Anne Mcgowan
    Cornell Journal of Law and Public Policy Volume 3 Article 10 Issue 2 Spring 1994 Learning the Hard Way: L-Tryptophan, the FDA, and the Regulation of Amino Acids Carter Anne McGowan Follow this and additional works at: http://scholarship.law.cornell.edu/cjlpp Part of the Law Commons Recommended Citation McGowan, Carter Anne (1994) "Learning the Hard Way: L-Tryptophan, the FDA, and the Regulation of Amino Acids," Cornell Journal of Law and Public Policy: Vol. 3: Iss. 2, Article 10. Available at: http://scholarship.law.cornell.edu/cjlpp/vol3/iss2/10 This Article is brought to you for free and open access by the Journals at Scholarship@Cornell Law: A Digital Repository. It has been accepted for inclusion in Cornell Journal of Law and Public Policy by an authorized administrator of Scholarship@Cornell Law: A Digital Repository. For more information, please contact [email protected]. LEARNING THE HARD WAY: L-TRYPTOPHAN, THE FDA, AND THE REGULATION OF AMINO ACIDS I sit before you helpless, broke, alone and in unyielding, relentless pain .... For those who have died and for those of us who live with cloudy futures, the lack of action is too little, too late. We have needed help with our orphan dis- ease. We need help now .... The U.S. Government is totally ineffective, and each agonizing day we grow more fragile. For those who appear to be in remission, we rejoice. But we cannot say with certainty that anyone is cured as long as the exact cause and cure is not found. For many of us, it is too late.
    [Show full text]
  • The Kynurenine Pathway As a Common Target for Ketamine and the Convergence of the Inflammation and Glutamate Hypotheses of Depression
    Neuropsychopharmacology (2013) 38, 1607–1608 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org Commentary Conceptual Confluence: The Kynurenine Pathway as a Common Target for Ketamine and the Convergence of the Inflammation and Glutamate Hypotheses of Depression Andrew H Miller*,1 1 Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA Neuropsychopharmacology (2013) 38, 1607–1608; doi:10.1038/npp.2013.140 Two of the dominant theories regarding the development of neurotrophic factor (BDNF), which is dependent upon depression and its response (or lack thereof) to conven- glutamate stimulation of alpha-amino-3-hydroxy-5-methyl- tional antidepressant therapies involve excessive activation 4-isoxazolepropionic acid (AMPA) receptors as a result of inflammatory pathways and alterations in glutamate of ketamine’s antagonism of NMDA receptors (Duman metabolism. Increased inflammation has been demon- et al, 2012). strated in a significant subset of depressed patients, and Interestingly, inflammatory cytokines have been shown to there appears to be a special relationship between interact with glutamate pathways in several important ways, inflammation and treatment resistance (Miller et al, 2009). including decreasing the expression of glutamate transpor- Indeed, increased inflammatory markers prior to antide- ters on relevant glial elements and increasing the release of pressant treatment predict treatment non-response, glutamate from astrocytes. Glutamate released by astrocytes and patients with treatment-resistant depression exhibit has preferential access to extrasynaptic NMDA receptors, increased inflammatory markers. Moreover, clinical factors which have been shown to decrease BDNF and increase related to treatment non-response are associated with excitotoxicity (Miller et al, 2009).
    [Show full text]
  • Chronic Quinolinic Acid Lesions in Rats Closely Resemble Huntington’S Disease
    The Journal of Neuroscience, June 1991, fI(6): 1649-l 659 Chronic Quinolinic Acid Lesions in Rats Closely Resemble Huntington’s Disease M. Flint Beal,’ Robert J. Ferrante,1*2 Kenton J. Swartz,1s3 and Neil W. Kowall’ ‘Neurochemistry and Experimental Neuropathology Laboratories, Neurology Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, *C. S. Kubik Laboratory of Neuropathology, James Homer Wright Laboratories, Massachusetts General Hospital, Boston, Massachusetts 02114, and 3Program in Neuroscience, Harvard Medical School and Harvard University, Boston, Massachusetts 02115 We previously found a relative sparing of somatostatin and populations. Striatal medium-sized spiny neurons containing neuropeptide Y neurons 1 week after producing striatal le- the neurochemicalmarkers GABA, substanceP, dynorphin, and sions with NMDA receptor agonists. These results are similar enkephalin are preferentially affected (Beal and Martin, 1986; to postmortem findings in Huntington’s disease (HD), though Ferrante et al., 1987b; Beal et al., 1988b). In contrast, medium- in this illness there are two- to threefold increases in striatal sized aspiny neuronscontaining the neuropeptidessomatostatin somatostatin and neuropeptide Y concentrations, which may and neuropeptide Y, and largeaspiny neuronscontaining ChAT be due to striatal atrophy. In the present study, we examined activity, are spared(Dawbam et al., 1985; Ferrante et al., 1985, the effects of striatal excitotoxin lesions at 6 months and 1 1987a; Beal et al., 1988b). Dopaminergic and serotonergic af- yr, because these lesions exhibit striatal shrinkage and at- ferent projections are also spared (Spokes, 1980; Beal et al., rophy similar to that occurring in HD striatum. At 6 months 1990b). and 1 yr, lesions with the NMDA receptor agonist quinolinic A suitable animal model of HD must replicate thesefeatures.
    [Show full text]